07:00 , Apr 13, 2015 |  BC Week In Review  |  Financial News

Euclises financial update

Euclises Pharmaceuticals Inc. , St. Louis, Mo.   Business: Cancer   Date announced: 2015-04-07   Note: Euclises raised $601,000 in a second close of a series A round, bringing the total raised in the round...
08:00 , Feb 16, 2015 |  BioCentury  |  Emerging Company Profile

COX-ing cancer into submission

Euclises Pharmaceuticals Inc. is developing two COX-2 inhibitor programs, one via a prodrug approach and one using deuteration, which are designed to minimize the gastrointestinal side effects that curtailed development of first-generation inhibitors for cancer....
07:00 , Sep 15, 2014 |  BC Week In Review  |  Financial News

Euclises completes venture financing

Euclises Pharmaceuticals Inc. , St. Louis, Mo.   Business: Cancer, Inflammation   Date completed: 2014-09-09   Type: Venture financing   Raised: $1.3 million   Investors: Cultivation Capital; BioGenerator; Missouri Technology Corp.; Analytical Bio-Chemistry Laboratories Inc.;...
07:00 , Sep 16, 2013 |  BioCentury  |  Emerging Company Profile

Tansna: Quieting convulsions

Propofol is used off-label in hospitals to treat uncontrolled seizures, but its potent sedative properties preclude everyday use. Tansna Therapeutics Inc. is developing non-sedating analogs of propofol that could help treat the one-third of epilepsy...